The Model Context Protocol (MCP) has emerged as the de facto standard for enabling Large Language Model (LLM) agents to interact with external tools, APIs, and databases. While MCP significantly extends agent capabilities, it introduces critical security vulnerabilities: tool poisoning attacks can inject malicious behavior into seemingly benign tools, and prompt injection can trick agents into leaking credentials or performing unauthorized actions. Current defense mechanisms—including prompt filtering, guardrails, and adversarial training—are heuristic and bypassable, with reported evasion rates reaching 100% against state-of-the-art systems.We present the Certified Tool Execution Framework (CTEF), the first provably secure defense against tool poisoning in MCP-based AI agents. CTEF employs a three-layer architecture: (1) capability-based access control (CAP-MCP) that enforces cryptographically unforgeable permissions, (2) formal pre/post-condition verification using Satisfiability Modulo Theories (SMT) solvers, and (3) sandboxed execution with syscall-level monitoring. We prove that CTEF achieves (ε, δ)-certified security, where ε < 2-128 represents the probability of accepting a poisoned tool and δ bounds the capability forgery risk.Through comprehensive evaluation on the MCP-Security benchmark comprising 50 benign and 30 poisoned tools across 6 attack categories, CTEF achieves 96.7% true positive rate and 3.2% false positive rate in poisoned tool detection—a 47% improvement over the next-best baseline. We establish theoretical sample complexity bounds showing that detecting a poisoned tool with violation probability, p requires Ω(1/p log 1/δ) samples. The framework incurs 2.3--8.7x execution overhead compared to unprotected MCP, acceptable for security-critical applications. CTEF enables safe deployment of autonomous AI agents in domains where tool integrity is paramount: healthcare decision support, financial trading, infrastructure management, and legal document processing. Our open-source implementation and benchmark are available on [anonymized for review].
No takes yet. Share an insight, caveat, or question.
Oppong et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: